Castle Biosciences Filed the paperwork on 6/26/19 for their $57 Million IPO. The commercial stage company provides diagnostic and prognostic test for dermatologic cancers. Castle intends to... read more
Castle Biosciences Filed the paperwork on 6/26/19 for their $57 Million IPO. The commercial stage company provides diagnostic and prognostic test for dermatologic cancers. Castle intends to... read more
Adaptive updated their IPO filing on 6/26/19 and raised their potential raise to $327 million from $230 million listed in their original filing. The company currently offers tools for monitoring... read more
Vesalius Biocapital III ('Vesalius'), a specialist life sciences venture capital investor, announced on 6/25/19 the final close of the VBC III fund securing EUR 120 million of equity commitments.... read more
Fulcrum Therapeutics filed the paperwork for there IPO to raise up to $86 million on 6/21/19. The company has three small molecule candidates in development that aim to treat the root cause of a... read more
